Chronic myelogenous leukemia, version 1.2015

Susan O'Brien; Jerald P. Radich; Camille N. Abboud; Mojtaba Akhtari; Jessica K. Altman; Ellin Berman; Peter Curtin; Daniel J. DeAngelo; Michael Deininger; Steven Devine; Amir T. Fathi; Jason Gotlib; Madan Jagasia; Patricia Kropf; Joseph O. Moore; Arnel Pallera; Vishnu V.B. Reddy; Neil P. Shah; B. Douglas Smith; David S. Snyder; Meir Wetzler; Kristina Gregory; Hema Sundar

doi:10.6004/jnccn.2014.0159

Chronic myelogenous leukemia, version 1.2015

Susan O'Brien, Jerald P. Radich, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Peter Curtin, Daniel J. DeAngelo, Michael Deininger, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Patricia Kropf, Joseph O. Moore, Arnel Pallera, Vishnu V.B. Reddy, Neil P. Shah, B. Douglas Smith, David S. SnyderMeir Wetzler, Kristina Gregory, Hema Sundar

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.

Original language	English
Pages (from-to)	1590-1610
Number of pages	21
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	12
Issue number	11
DOIs	https://doi.org/10.6004/jnccn.2014.0159
State	Published - Nov 1 2014

Access to Document

10.6004/jnccn.2014.0159

Cite this

O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., Curtin, P., DeAngelo, D. J., Deininger, M., Devine, S., Fathi, A. T., Gotlib, J., Jagasia, M., Kropf, P., Moore, J. O., Pallera, A., Reddy, V. V. B., Shah, N. P., Smith, B. D., ... Sundar, H. (2014). Chronic myelogenous leukemia, version 1.2015. JNCCN Journal of the National Comprehensive Cancer Network, 12(11), 1590-1610. https://doi.org/10.6004/jnccn.2014.0159

@article{e370391946d94a73b68489a1b2f7b2c4,

title = "Chronic myelogenous leukemia, version 1.2015",

abstract = "Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.",

author = "Susan O'Brien and Radich, {Jerald P.} and Abboud, {Camille N.} and Mojtaba Akhtari and Altman, {Jessica K.} and Ellin Berman and Peter Curtin and DeAngelo, {Daniel J.} and Michael Deininger and Steven Devine and Fathi, {Amir T.} and Jason Gotlib and Madan Jagasia and Patricia Kropf and Moore, {Joseph O.} and Arnel Pallera and Reddy, {Vishnu V.B.} and Shah, {Neil P.} and Smith, {B. Douglas} and Snyder, {David S.} and Meir Wetzler and Kristina Gregory and Hema Sundar",

year = "2014",

month = nov,

day = "1",

doi = "10.6004/jnccn.2014.0159",

language = "English",

volume = "12",

pages = "1590--1610",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "11",

}

O'Brien, S, Radich, JP, Abboud, CN, Akhtari, M, Altman, JK, Berman, E, Curtin, P, DeAngelo, DJ, Deininger, M, Devine, S, Fathi, AT, Gotlib, J, Jagasia, M, Kropf, P, Moore, JO, Pallera, A, Reddy, VVB, Shah, NP, Smith, BD, Snyder, DS, Wetzler, M, Gregory, K & Sundar, H 2014, 'Chronic myelogenous leukemia, version 1.2015', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 11, pp. 1590-1610. https://doi.org/10.6004/jnccn.2014.0159

TY - JOUR

T1 - Chronic myelogenous leukemia, version 1.2015

AU - O'Brien, Susan

AU - Radich, Jerald P.

AU - Abboud, Camille N.

AU - Akhtari, Mojtaba

AU - Altman, Jessica K.

AU - Berman, Ellin

AU - Curtin, Peter

AU - DeAngelo, Daniel J.

AU - Deininger, Michael

AU - Devine, Steven

AU - Fathi, Amir T.

AU - Gotlib, Jason

AU - Jagasia, Madan

AU - Kropf, Patricia

AU - Moore, Joseph O.

AU - Pallera, Arnel

AU - Reddy, Vishnu V.B.

AU - Shah, Neil P.

AU - Smith, B. Douglas

AU - Snyder, David S.

AU - Wetzler, Meir

AU - Gregory, Kristina

AU - Sundar, Hema

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.

AB - Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.

UR - http://www.scopus.com/inward/record.url?scp=84908539399&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0159

DO - 10.6004/jnccn.2014.0159

M3 - Article

C2 - 25361806

AN - SCOPUS:84908539399

SN - 1540-1405

VL - 12

SP - 1590

EP - 1610

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 11

ER -

Chronic myelogenous leukemia, version 1.2015

Abstract

Access to Document

Other files and links

Fingerprint

Cite this